Royalty Pharma Sets Nov. 4 Date for Third-Quarter 2026 Results

Royalty Pharma plc will release its third-quarter 2026 financial results on Nov. 4 before U.S. markets open, giving investors the company’s next update on royalty income and operating cash flow.

The company will host a conference call and simultaneous webcast at 8 a.m. ET (1 p.m. UTC) the same day. Details will be available through Royalty Pharma’s investor-events page, and the replay will remain archived for at least 30 days.

Royalty Pharma’s second-quarter Portfolio Receipts totaled $773 million, while net cash from operating activities reached $728 million. The company raised its full-year 2026 Portfolio Receipts guidance to $3.4 billion to $3.5 billion.

Royalty Pharma acquires biopharmaceutical royalty interests and helps fund drug development through royalty transactions and co-funding agreements. Its portfolio includes royalties tied to Trikafta, Trelegy, Evrysdi, Tremfya and Tysabri.

The company’s third-quarter results are scheduled for release Nov. 4 before U.S. markets open.